fostamatinib


( Last Updated : June 23, 2021)
Generic Name:
fostamatinib
Project Status:
Received
Therapeutic Area:
Chronic immune thrombocytopenia
Call for patient/clinician input open:
Brand Name:
Tavalisse
Project Line:
Reimbursement Review
Project Number:
SR0701-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
​For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other treatments.
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
N/A
Indications:
​For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other treatments.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openJune 23, 2021
Call for patient/clinician input closedAugust 16, 2021
Submission receivedJuly 22, 2021
Submission accepted